ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ORGO • US68621F1021

3.84 USD
+0.01 (+0.26%)
At close: Feb 10, 2026
3.91 USD
+0.07 (+1.82%)
After Hours: 2/10/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

ORGO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year ORGO was profitable.
  • ORGO had a negative operating cash flow in the past year.
  • Of the past 5 years ORGO 4 years were profitable.
  • In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -2.63%, ORGO belongs to the top of the industry, outperforming 87.38% of the companies in the same industry.
  • ORGO's Return On Equity of -3.47% is amongst the best of the industry. ORGO outperforms 89.10% of its industry peers.
  • ORGO has a better Return On Invested Capital (0.16%) than 88.72% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for ORGO is significantly below the industry average of 18.27%.
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROIC 0.16%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • ORGO's Operating Margin of 0.18% is amongst the best of the industry. ORGO outperforms 88.72% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has declined.
  • The Gross Margin of ORGO (74.49%) is better than 83.37% of its industry peers.
  • In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
Industry RankSector Rank
OM 0.18%
PM (TTM) N/A
GM 74.49%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • ORGO has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ORGO has more shares outstanding
  • The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.64 indicates that ORGO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of ORGO (3.64) is better than 69.79% of its industry peers.
  • ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ORGO (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.64
ROIC/WACC0.01
WACC12.78%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 3.32 indicates that ORGO has no problem at all paying its short term obligations.
  • ORGO has a Current ratio of 3.32. This is in the lower half of the industry: ORGO underperforms 60.04% of its industry peers.
  • ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO has a worse Quick ratio (2.88) than 63.48% of its industry peers.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 2.88
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ORGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -90.91%.
  • Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
  • Looking at the last year, ORGO shows a small growth in Revenue. The Revenue has grown by 2.24% in the last year.
  • The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.27% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 8.70% on average per year.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 384.00, ORGO can be considered very expensive at the moment.
  • ORGO's Price/Earnings ratio is rather cheap when compared to the industry. ORGO is cheaper than 88.72% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.03, ORGO is valued quite expensively.
  • With a Price/Forward Earnings ratio of 25.96, ORGO can be considered very expensive at the moment.
  • 92.35% of the companies in the same industry are more expensive than ORGO, based on the Price/Forward Earnings ratio.
  • ORGO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.97, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 384
Fwd PE 25.96
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • 93.69% of the companies in the same industry are more expensive than ORGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.35
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • ORGO has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (2/10/2026, 8:00:02 PM)

After market: 3.91 +0.07 (+1.82%)

3.84

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners54.62%
Inst Owner Change0.03%
Ins Owners31.34%
Ins Owner Change-0.43%
Market Cap487.33M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (125.78%)
Short Float %19.11%
Short Ratio10.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE 384
Fwd PE 25.96
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.4
EV/EBITDA 22.35
EPS(TTM)0.01
EY0.26%
EPS(NY)0.15
Fwd EY3.85%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.19%
ROICexgc 0.21%
OM 0.18%
PM (TTM) N/A
GM 74.49%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.11
Cap/Depr 70.73%
Cap/Sales 2.76%
Interest Coverage 0.99
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.32
Quick Ratio 2.88
Altman-Z 3.64
F-Score2
WACC12.78%
ROIC/WACC0.01
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.